Is AURA or KRRO more profitable?

Aura Biosciences has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Aura Biosciences' return on equity of -78.12% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Aura Biosciences N/A -78.12% -64.08% Korro Bio -1,834.48% -117.86% -71.04%

Does the media favor AURA or KRRO?

In the previous week, Korro Bio had 12 more articles in the media than Aura Biosciences. MarketBeat recorded 13 mentions for Korro Bio and 1 mentions for Aura Biosciences. Korro Bio's average media sentiment score of 0.96 beat Aura Biosciences' score of 0.00 indicating that Korro Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aura Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Korro Bio 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, KRRO or BIOA?

BioAge Labs has higher revenue and earnings than Korro Bio. BioAge Labs is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Korro Bio $3.84M 40.24 -$117.26M -$11.67 N/A BioAge Labs $10.32M 67.65 -$80.61M -$2.40 N/A

Is KRRO or BIOA more profitable?

BioAge Labs has a net margin of -871.75% compared to Korro Bio's net margin of -1,834.48%. BioAge Labs' return on equity of -29.40% beat Korro Bio's return on equity. Company Net Margins Return on Equity Return on Assets Korro Bio -1,834.48% -117.86% -71.04% BioAge Labs -871.75% -29.40% -27.26%

Does the media prefer KRRO or BIOA?

In the previous week, Korro Bio had 12 more articles in the media than BioAge Labs. MarketBeat recorded 13 mentions for Korro Bio and 1 mentions for BioAge Labs. Korro Bio's average media sentiment score of 0.96 beat BioAge Labs' score of -1.08 indicating that Korro Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Korro Bio 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioAge Labs 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Negative

Does the media prefer PHAT or KRRO?

In the previous week, Korro Bio had 12 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 13 mentions for Korro Bio and 1 mentions for Phathom Pharmaceuticals. Korro Bio's average media sentiment score of 0.96 beat Phathom Pharmaceuticals' score of 0.00 indicating that Korro Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Phathom Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Korro Bio 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ALLO or KRRO?

In the previous week, Korro Bio had 9 more articles in the media than Allogene Therapeutics. MarketBeat recorded 13 mentions for Korro Bio and 4 mentions for Allogene Therapeutics. Korro Bio's average media sentiment score of 0.96 beat Allogene Therapeutics' score of 0.67 indicating that Korro Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Korro Bio 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to KRRO or SLDB?

In the previous week, Solid Biosciences had 3 more articles in the media than Korro Bio. MarketBeat recorded 16 mentions for Solid Biosciences and 13 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.96 beat Solid Biosciences' score of 0.10 indicating that Korro Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Korro Bio 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Solid Biosciences 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Korro Bio (KRRO) Competitors

$10.72 0.00 (0.00%)

Closing price 06/5/2026 04:00 PM Eastern

Extended Trading

$10.51 -0.21 (-1.94%)

As of 04:07 AM Eastern

Compare

KRRO vs. AURA, BIOA, PHAT, ALLO, and SLDB

Should you buy Korro Bio stock or one of its competitors? MarketBeat compares Korro Bio with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Korro Bio include Aura Biosciences (AURA), BioAge Labs (BIOA), Phathom Pharmaceuticals (PHAT), Allogene Therapeutics (ALLO), and Solid Biosciences (SLDB). These companies are all part of the "pharmaceutical products" industry.

How does Korro Bio compare to Aura Biosciences?

Aura Biosciences (NASDAQ:AURA) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, valuation, earnings, institutional ownership, risk, analyst recommendations and profitability.

Aura Biosciences has a beta of 0.39, meaning that its share price is 61% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3, meaning that its share price is 200% more volatile than the broader market.

Aura Biosciences currently has a consensus target price of $20.50, suggesting a potential upside of 209.20%. Korro Bio has a consensus target price of $16.71, suggesting a potential upside of 55.92%. Given Aura Biosciences' higher probable upside, analysts plainly believe Aura Biosciences is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aura Biosciences	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

Aura Biosciences has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Aura Biosciences' return on equity of -78.12% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aura Biosciences	N/A	-78.12%	-64.08%
Korro Bio	-1,834.48%	-117.86%	-71.04%

In the previous week, Korro Bio had 12 more articles in the media than Aura Biosciences. MarketBeat recorded 13 mentions for Korro Bio and 1 mentions for Aura Biosciences. Korro Bio's average media sentiment score of 0.96 beat Aura Biosciences' score of 0.00 indicating that Korro Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aura Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Korro Bio	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 6.3% of Aura Biosciences shares are held by insiders. Comparatively, 4.8% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Aura Biosciences has higher earnings, but lower revenue than Korro Bio. Aura Biosciences is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aura Biosciences	N/A	N/A	-$106.19M	-$1.74	N/A
Korro Bio	$3.84M	40.24	-$117.26M	-$11.67	N/A

Summary

Aura Biosciences and Korro Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Korro Bio compare to BioAge Labs?

Korro Bio (NASDAQ:KRRO) and BioAge Labs (NASDAQ:BIOA) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, analyst recommendations, institutional ownership, profitability, dividends, risk and media sentiment.

13.2% of Korro Bio shares are held by institutional investors. 4.8% of Korro Bio shares are held by company insiders. Comparatively, 20.8% of BioAge Labs shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Korro Bio currently has a consensus target price of $16.71, suggesting a potential upside of 55.92%. BioAge Labs has a consensus target price of $43.50, suggesting a potential upside of 177.07%. Given BioAge Labs' higher possible upside, analysts plainly believe BioAge Labs is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
BioAge Labs	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Korro Bio has a beta of 3, suggesting that its share price is 200% more volatile than the broader market. Comparatively, BioAge Labs has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

In the previous week, Korro Bio had 12 more articles in the media than BioAge Labs. MarketBeat recorded 13 mentions for Korro Bio and 1 mentions for BioAge Labs. Korro Bio's average media sentiment score of 0.96 beat BioAge Labs' score of -1.08 indicating that Korro Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Korro Bio	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioAge Labs	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Negative

BioAge Labs has higher revenue and earnings than Korro Bio. BioAge Labs is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$3.84M	40.24	-$117.26M	-$11.67	N/A
BioAge Labs	$10.32M	67.65	-$80.61M	-$2.40	N/A

BioAge Labs has a net margin of -871.75% compared to Korro Bio's net margin of -1,834.48%. BioAge Labs' return on equity of -29.40% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-117.86%	-71.04%
BioAge Labs	-871.75%	-29.40%	-27.26%

Summary

BioAge Labs beats Korro Bio on 9 of the 16 factors compared between the two stocks.

How does Korro Bio compare to Phathom Pharmaceuticals?

Phathom Pharmaceuticals (NASDAQ:PHAT) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

99.0% of Phathom Pharmaceuticals shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 9.3% of Phathom Pharmaceuticals shares are held by company insiders. Comparatively, 4.8% of Korro Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Korro Bio had 12 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 13 mentions for Korro Bio and 1 mentions for Phathom Pharmaceuticals. Korro Bio's average media sentiment score of 0.96 beat Phathom Pharmaceuticals' score of 0.00 indicating that Korro Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Phathom Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Korro Bio	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Korro Bio has lower revenue, but higher earnings than Phathom Pharmaceuticals. Phathom Pharmaceuticals is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phathom Pharmaceuticals	$175.11M	4.61	-$221.25M	-$2.12	N/A
Korro Bio	$3.84M	40.24	-$117.26M	-$11.67	N/A

Phathom Pharmaceuticals currently has a consensus target price of $24.50, suggesting a potential upside of 141.86%. Korro Bio has a consensus target price of $16.71, suggesting a potential upside of 55.92%. Given Phathom Pharmaceuticals' higher probable upside, equities research analysts plainly believe Phathom Pharmaceuticals is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phathom Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.86
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

Phathom Pharmaceuticals has a net margin of -76.77% compared to Korro Bio's net margin of -1,834.48%. Phathom Pharmaceuticals' return on equity of 0.00% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phathom Pharmaceuticals	-76.77%	N/A	-44.29%
Korro Bio	-1,834.48%	-117.86%	-71.04%

Phathom Pharmaceuticals has a beta of 0.51, indicating that its share price is 49% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3, indicating that its share price is 200% more volatile than the broader market.

Summary

Korro Bio beats Phathom Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Korro Bio compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and Korro Bio (NASDAQ:KRRO) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, earnings, risk, dividends, institutional ownership, media sentiment and profitability.

Allogene Therapeutics currently has a consensus target price of $8.52, suggesting a potential upside of 353.31%. Korro Bio has a consensus target price of $16.71, suggesting a potential upside of 55.92%. Given Allogene Therapeutics' higher possible upside, equities research analysts plainly believe Allogene Therapeutics is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92

In the previous week, Korro Bio had 9 more articles in the media than Allogene Therapeutics. MarketBeat recorded 13 mentions for Korro Bio and 4 mentions for Allogene Therapeutics. Korro Bio's average media sentiment score of 0.96 beat Allogene Therapeutics' score of 0.67 indicating that Korro Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Korro Bio	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Allogene Therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market. Comparatively, Korro Bio has a beta of 3, indicating that its stock price is 200% more volatile than the broader market.

Allogene Therapeutics has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Allogene Therapeutics' return on equity of -56.45% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
Korro Bio	-1,834.48%	-117.86%	-71.04%

Korro Bio has higher revenue and earnings than Allogene Therapeutics. Allogene Therapeutics is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	32,444.10	-$190.89M	-$0.77	N/A
Korro Bio	$3.84M	40.24	-$117.26M	-$11.67	N/A

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 13.2% of Korro Bio shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by insiders. Comparatively, 4.8% of Korro Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Allogene Therapeutics beats Korro Bio on 9 of the 17 factors compared between the two stocks.

How does Korro Bio compare to Solid Biosciences?

Korro Bio (NASDAQ:KRRO) and Solid Biosciences (NASDAQ:SLDB) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership, earnings and media sentiment.

13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 81.5% of Solid Biosciences shares are owned by institutional investors. 4.8% of Korro Bio shares are owned by company insiders. Comparatively, 2.7% of Solid Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Solid Biosciences had 3 more articles in the media than Korro Bio. MarketBeat recorded 16 mentions for Solid Biosciences and 13 mentions for Korro Bio. Korro Bio's average media sentiment score of 0.96 beat Solid Biosciences' score of 0.10 indicating that Korro Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Korro Bio	3 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Solid Biosciences	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Korro Bio has higher revenue and earnings than Solid Biosciences. Solid Biosciences is trading at a lower price-to-earnings ratio than Korro Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Korro Bio	$3.84M	40.24	-$117.26M	-$11.67	N/A
Solid Biosciences	N/A	N/A	-$174.32M	-$1.95	N/A

Korro Bio has a beta of 3, suggesting that its share price is 200% more volatile than the broader market. Comparatively, Solid Biosciences has a beta of 2.43, suggesting that its share price is 143% more volatile than the broader market.

Solid Biosciences has a net margin of 0.00% compared to Korro Bio's net margin of -1,834.48%. Solid Biosciences' return on equity of -73.42% beat Korro Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Korro Bio	-1,834.48%	-117.86%	-71.04%
Solid Biosciences	N/A	-73.42%	-61.13%

Korro Bio presently has a consensus price target of $16.71, indicating a potential upside of 55.92%. Solid Biosciences has a consensus price target of $17.00, indicating a potential upside of 153.73%. Given Solid Biosciences' higher possible upside, analysts plainly believe Solid Biosciences is more favorable than Korro Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Korro Bio	1 Sell rating(s)	2 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	2.92
Solid Biosciences	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.92

Summary

Solid Biosciences beats Korro Bio on 8 of the 15 factors compared between the two stocks.

Get Korro Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KRRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KRRO vs. The Competition

Export

Metric	Korro Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$154.62M	$2.93B	$6.47B	$11.98B
Dividend Yield	N/A	1.70%	2.67%	5.55%
P/E Ratio	-0.92	18.12	24.08	23.62
Price / Sales	40.24	293.81	516.49	109.93
Price / Cash	N/A	56.17	26.99	37.25
Price / Book	1.96	3.83	10.39	6.66
Net Income	-$117.26M	$75.85M	$3.57B	$337.72M
7 Day Performance	-17.09%	-4.02%	-0.92%	-3.71%
1 Month Performance	-11.04%	-5.35%	3.55%	0.97%
1 Year Performance	-26.53%	14.98%	23.80%	25.35%

Korro Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KRRO Korro Bio	3.535 of 5 stars	$10.72 flat	$16.71 +55.9%	-26.5%	$154.62M	$3.84M	N/A	70	Gap Up
AURA Aura Biosciences	2.3849 of 5 stars	$6.87 -4.5%	$20.50 +198.4%	+2.0%	$772.30M	N/A	N/A	50	Gap Up
BIOA BioAge Labs	3.1484 of 5 stars	$16.55 -3.8%	$43.50 +162.9%	N/A	$768.59M	$10.32M	N/A	N/A
PHAT Phathom Pharmaceuticals	1.905 of 5 stars	$9.55 +3.4%	$25.00 +161.8%	+13.6%	$764.86M	$204.89M	N/A	110	Gap Down
ALLO Allogene Therapeutics	2.9265 of 5 stars	$2.09 -3.0%	$8.52 +308.7%	+32.4%	$748.99M	N/A	N/A	310	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KRRO) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Korro Bio (KRRO) Competitors

KRRO vs. AURA, BIOA, PHAT, ALLO, and SLDB

How does Korro Bio compare to Aura Biosciences?

Summary

How does Korro Bio compare to BioAge Labs?

Summary

How does Korro Bio compare to Phathom Pharmaceuticals?

Summary

How does Korro Bio compare to Allogene Therapeutics?

Summary

How does Korro Bio compare to Solid Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO vs. The Competition

Korro Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Korro Bio (KRRO) Competitors

KRRO vs. AURA, BIOA, PHAT, ALLO, and SLDB

How does Korro Bio compare to Aura Biosciences?

Which has more risk and volatility, AURA or KRRO?

Do analysts prefer AURA or KRRO?

Is AURA or KRRO more profitable?

Does the media favor AURA or KRRO?

Do insiders and institutionals believe in AURA or KRRO?

Which has stronger earnings & valuation, AURA or KRRO?

Summary

How does Korro Bio compare to BioAge Labs?

Do insiders & institutionals hold more shares of KRRO or BIOA?

Do analysts rate KRRO or BIOA?

Which has more volatility and risk, KRRO or BIOA?

Does the media prefer KRRO or BIOA?

Which has stronger earnings & valuation, KRRO or BIOA?

Is KRRO or BIOA more profitable?

Summary

How does Korro Bio compare to Phathom Pharmaceuticals?

Do institutionals and insiders hold more shares of PHAT or KRRO?

Does the media prefer PHAT or KRRO?

Which has better valuation & earnings, PHAT or KRRO?

Do analysts prefer PHAT or KRRO?

Is PHAT or KRRO more profitable?

Which has more risk and volatility, PHAT or KRRO?

Summary

How does Korro Bio compare to Allogene Therapeutics?

Do analysts recommend ALLO or KRRO?

Does the media prefer ALLO or KRRO?

Which has more volatility & risk, ALLO or KRRO?

Is ALLO or KRRO more profitable?

Which has higher valuation and earnings, ALLO or KRRO?

Do institutionals & insiders have more ownership in ALLO or KRRO?

Summary

How does Korro Bio compare to Solid Biosciences?

Do institutionals and insiders have more ownership in KRRO or SLDB?

Does the media refer more to KRRO or SLDB?

Which has higher earnings and valuation, KRRO or SLDB?

Which has more volatility & risk, KRRO or SLDB?

Is KRRO or SLDB more profitable?

Do analysts rate KRRO or SLDB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KRRO vs. The Competition

Korro Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools